CA2648931C - Method and apparatus for the non-invasive measurement of tissue function and metabolism by determination of steady-state fluorescence anisotropy - Google Patents
Method and apparatus for the non-invasive measurement of tissue function and metabolism by determination of steady-state fluorescence anisotropy Download PDFInfo
- Publication number
- CA2648931C CA2648931C CA2648931A CA2648931A CA2648931C CA 2648931 C CA2648931 C CA 2648931C CA 2648931 A CA2648931 A CA 2648931A CA 2648931 A CA2648931 A CA 2648931A CA 2648931 C CA2648931 C CA 2648931C
- Authority
- CA
- Canada
- Prior art keywords
- tissue
- fluorescence anisotropy
- steady
- stimulated
- resting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000198 fluorescence anisotropy Methods 0.000 title claims abstract description 161
- 238000000034 method Methods 0.000 title claims description 86
- 230000004060 metabolic process Effects 0.000 title claims description 40
- 238000005259 measurement Methods 0.000 title abstract description 47
- 201000010099 disease Diseases 0.000 claims abstract description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 47
- 230000004936 stimulating effect Effects 0.000 claims abstract 6
- 210000001519 tissue Anatomy 0.000 claims description 219
- 230000000284 resting effect Effects 0.000 claims description 49
- 230000002503 metabolic effect Effects 0.000 claims description 32
- 230000006870 function Effects 0.000 claims description 26
- 230000005284 excitation Effects 0.000 claims description 21
- 108010028127 Dihydrolipoamide Dehydrogenase Proteins 0.000 claims description 20
- 102000028526 Dihydrolipoamide Dehydrogenase Human genes 0.000 claims description 20
- 238000003384 imaging method Methods 0.000 claims description 19
- 230000008859 change Effects 0.000 claims description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 16
- 239000001301 oxygen Substances 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 13
- 230000010287 polarization Effects 0.000 claims description 13
- 230000000638 stimulation Effects 0.000 claims description 13
- 238000011065 in-situ storage Methods 0.000 claims description 11
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 9
- 206010030348 Open-Angle Glaucoma Diseases 0.000 claims description 9
- 239000008103 glucose Substances 0.000 claims description 9
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 9
- 201000006366 primary open angle glaucoma Diseases 0.000 claims description 9
- 230000006735 deficit Effects 0.000 claims description 8
- 230000001678 irradiating effect Effects 0.000 claims description 8
- 230000004066 metabolic change Effects 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 7
- 210000003470 mitochondria Anatomy 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 210000003679 cervix uteri Anatomy 0.000 claims description 4
- 210000003238 esophagus Anatomy 0.000 claims description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
- 230000000670 limiting effect Effects 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 208000020911 optic nerve disease Diseases 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 claims description 3
- 230000001066 destructive effect Effects 0.000 claims description 3
- 208000012268 mitochondrial disease Diseases 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 238000009738 saturating Methods 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 230000007704 transition Effects 0.000 claims description 3
- 238000011156 evaluation Methods 0.000 claims 6
- 230000009092 tissue dysfunction Effects 0.000 claims 4
- 230000003187 abdominal effect Effects 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 230000007170 pathology Effects 0.000 claims 3
- 230000000153 supplemental effect Effects 0.000 claims 1
- 210000001525 retina Anatomy 0.000 description 31
- 241001465754 Metazoa Species 0.000 description 18
- 230000029058 respiratory gaseous exchange Effects 0.000 description 17
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 15
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 15
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 14
- 206010025421 Macule Diseases 0.000 description 12
- 230000006378 damage Effects 0.000 description 12
- 210000004204 blood vessel Anatomy 0.000 description 10
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 230000002123 temporal effect Effects 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 108010057573 Flavoproteins Proteins 0.000 description 8
- 102000003983 Flavoproteins Human genes 0.000 description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000002427 irreversible effect Effects 0.000 description 7
- 241000282693 Cercopithecidae Species 0.000 description 6
- 208000010412 Glaucoma Diseases 0.000 description 6
- 206010030043 Ocular hypertension Diseases 0.000 description 6
- 238000013536 ocular coherence tomography Methods 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 210000003733 optic disk Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- 230000033115 angiogenesis Effects 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000000994 depressogenic effect Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 230000037323 metabolic rate Effects 0.000 description 4
- 229960003966 nicotinamide Drugs 0.000 description 4
- 235000005152 nicotinamide Nutrition 0.000 description 4
- 239000011570 nicotinamide Substances 0.000 description 4
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 108010079426 Electron-Transferring Flavoproteins Proteins 0.000 description 3
- 102000012737 Electron-Transferring Flavoproteins Human genes 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 3
- 241000566604 Sturnella Species 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 230000005281 excited state Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 229950006238 nadide Drugs 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 150000003222 pyridines Chemical class 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 208000004644 retinal vein occlusion Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 201000007917 background diabetic retinopathy Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 238000005558 fluorometry Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 235000020938 metabolic status Nutrition 0.000 description 2
- 230000006677 mitochondrial metabolism Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 230000000287 tissue oxygenation Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- YPZRHBJKEMOYQH-UYBVJOGSSA-L FADH2(2-) Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP([O-])(=O)OP([O-])(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(NC(=O)NC2=O)=C2NC2=C1C=C(C)C(C)=C2 YPZRHBJKEMOYQH-UYBVJOGSSA-L 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 101100202428 Neopyropia yezoensis atps gene Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 230000002715 bioenergetic effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000013172 carotid endarterectomy Methods 0.000 description 1
- 230000006567 cellular energy metabolism Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- 238000013534 fluorescein angiography Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000012014 optical coherence tomography Methods 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000000759 time-resolved fluorescence anisotropy Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
- A61B5/14555—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases specially adapted for the eye fundus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
- A61B5/14556—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases by fluorescence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4842—Monitoring progression or stage of a disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7246—Details of waveform analysis using correlation, e.g. template matching or determination of similarity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7278—Artificial waveform generation or derivation, e.g. synthesizing signals from measured signals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
- G01N2021/6484—Optical fibres
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6445—Measuring fluorescence polarisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2201/00—Features of devices classified in G01N21/00
- G01N2201/06—Illumination; Optics
- G01N2201/068—Optics, miscellaneous
- G01N2201/0683—Brewster plate; polarisation controlling elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2201/00—Features of devices classified in G01N21/00
- G01N2201/12—Circuits of general importance; Signal processing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Signal Processing (AREA)
- Artificial Intelligence (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Eye Examination Apparatus (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74483106P | 2006-04-13 | 2006-04-13 | |
| US60/744,831 | 2006-04-13 | ||
| US11/624,820 US8129105B2 (en) | 2006-04-13 | 2007-01-19 | Method and apparatus for the non-invasive measurement of tissue function and metabolism by determination of steady-state fluorescence anisotropy |
| US11/624,820 | 2007-01-19 | ||
| PCT/US2007/063768 WO2007121009A2 (en) | 2006-04-13 | 2007-03-12 | Method and apparatus for the non-invasive measurement of tissue function and metabolism by determination of steady-state fluorescence anisotropy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2648931A1 CA2648931A1 (en) | 2007-10-25 |
| CA2648931C true CA2648931C (en) | 2017-06-13 |
Family
ID=38605233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2648931A Active CA2648931C (en) | 2006-04-13 | 2007-03-12 | Method and apparatus for the non-invasive measurement of tissue function and metabolism by determination of steady-state fluorescence anisotropy |
Country Status (6)
| Country | Link |
|---|---|
| US (9) | US8129105B2 (enExample) |
| EP (1) | EP2004040A4 (enExample) |
| JP (3) | JP2009533160A (enExample) |
| AU (1) | AU2007238412B2 (enExample) |
| CA (1) | CA2648931C (enExample) |
| WO (1) | WO2007121009A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2904927B1 (fr) * | 2006-08-17 | 2018-05-18 | Mauna Kea Technologies | Utilisation d'un systeme d'imagerie par fluorescence confocale fibre in vivo in situ, systeme et procede d'imagerie par fluorescence confocale fibres in vivo in situ |
| US8270689B2 (en) | 2006-09-12 | 2012-09-18 | Carestream Health, Inc. | Apparatus for caries detection |
| US20080214940A1 (en) * | 2007-03-02 | 2008-09-04 | Benaron David A | Medical imaging lens system, and method with high-efficiency light collection and collinear illumination |
| TW200927060A (en) | 2007-11-05 | 2009-07-01 | Kci Licensing Inc | Identification of tissue for debridement |
| US8403862B2 (en) * | 2007-12-20 | 2013-03-26 | Yeda Research And Development Co. Ltd. | Time-based imaging |
| JP2011521237A (ja) | 2008-05-20 | 2011-07-21 | ユニバーシティー ヘルス ネットワーク | 螢光に基づく画像化およびモニタリング用装置ならびにその方法 |
| JP5543126B2 (ja) * | 2009-04-16 | 2014-07-09 | キヤノン株式会社 | 医用画像処理装置及びその制御方法 |
| KR101889575B1 (ko) * | 2010-11-05 | 2018-08-17 | 시노케어 메디텍, 인크. | 당뇨병의 검출을 위한 개선된 알고리즘 |
| JP5816486B2 (ja) * | 2011-08-18 | 2015-11-18 | オリンパス株式会社 | 蛍光観察装置および蛍光観察システム並びに蛍光観察装置の蛍光画像処理方法 |
| WO2013044182A1 (en) | 2011-09-22 | 2013-03-28 | The George Washington University | Systems and methods for visualizing ablated tissue |
| US9014789B2 (en) | 2011-09-22 | 2015-04-21 | The George Washington University | Systems and methods for visualizing ablated tissue |
| US9677869B2 (en) | 2012-12-05 | 2017-06-13 | Perimeter Medical Imaging, Inc. | System and method for generating a wide-field OCT image of a portion of a sample |
| EP3068288A4 (en) * | 2013-11-14 | 2017-07-26 | The George Washington University | Systems and methods for determining lesion depth using fluorescence imaging |
| WO2015073871A2 (en) | 2013-11-14 | 2015-05-21 | The George Washington University | Systems and methods for determining lesion depth using fluorescence imaging |
| WO2015077474A1 (en) | 2013-11-20 | 2015-05-28 | The George Washington University | Systems and methods for hyperspectral analysis of cardiac tissue |
| CN115989999A (zh) | 2014-07-24 | 2023-04-21 | 大学健康网络 | 用于诊断目的的数据的收集和分析 |
| US10143517B2 (en) | 2014-11-03 | 2018-12-04 | LuxCath, LLC | Systems and methods for assessment of contact quality |
| US10722301B2 (en) | 2014-11-03 | 2020-07-28 | The George Washington University | Systems and methods for lesion assessment |
| EP3081163B1 (en) * | 2015-04-12 | 2021-10-20 | Taiwan Biophotonic Corporation | Module, device and method for optical measurement |
| WO2016166067A1 (en) | 2015-04-17 | 2016-10-20 | Koninklijke Philips N.V. | Detection of anisotropic biological tissue |
| US10779904B2 (en) | 2015-07-19 | 2020-09-22 | 460Medical, Inc. | Systems and methods for lesion formation and assessment |
| CN107922963A (zh) * | 2015-08-26 | 2018-04-17 | 仓敷纺绩株式会社 | 细胞测定方法 |
| WO2018016409A1 (ja) * | 2016-07-19 | 2018-01-25 | 株式会社アサヒビジョン | 眼球分析装置および眼球分析方法 |
| WO2018016410A1 (ja) * | 2016-07-19 | 2018-01-25 | 株式会社アサヒビジョン | 眼球分析装置および眼球分析方法 |
| US10201306B2 (en) * | 2016-08-30 | 2019-02-12 | Konica Minolta Laboratory U.S.A., Inc. | Method and system for capturing images for wound assessment with self color compensation |
| WO2018231724A1 (en) * | 2017-06-12 | 2018-12-20 | Trustees Of Boston University | Systems and methods for oblique laser scanning |
| EP3655748B1 (en) | 2017-07-18 | 2023-08-09 | Perimeter Medical Imaging, Inc. | Sample container for stabilizing and aligning excised biological tissue samples for ex vivo analysis |
| CN109100325B (zh) * | 2018-06-14 | 2020-12-25 | 东南大学 | 一种基于光谱吸收率二次谐波特征提取的气体浓度测量方法 |
| WO2019245946A1 (en) * | 2018-06-18 | 2019-12-26 | Calico Life Sciences Llc | System and method for inferring protein binding |
| CA3106042A1 (en) * | 2018-08-29 | 2020-03-05 | Wisconsin Alumni Research Foundation | Systems and methods for sorting t cells by activation state |
| DE102019006971A1 (de) * | 2019-10-07 | 2021-04-08 | aquila biolabs GmbH | Verfahren und Vorrichtung zur Bestimmung des Zustands von Zellen in Reaktoren |
| KR102116232B1 (ko) * | 2019-11-12 | 2020-05-28 | (주)로고스바이오시스템스 | 시료 검출 장치 및 이를 이용한 시료 검출 방법 |
| CN115103647A (zh) | 2020-01-08 | 2022-09-23 | 460医学股份有限公司 | 用于消融损伤的光学询问的系统和方法 |
| WO2021174160A1 (en) | 2020-02-28 | 2021-09-02 | Preformed Line Products Co. | Cable spacer comprising a ratchet spacer clamp |
| US12016656B2 (en) * | 2020-10-09 | 2024-06-25 | QuantuMed Pty Ltd | Cellular ionic activity visualisation |
| KR102553788B1 (ko) * | 2021-01-20 | 2023-07-12 | 연세대학교 산학협력단 | 시료의 광학적 이방성을 정량화하는 현미경 시스템 |
| US20230085578A1 (en) * | 2021-09-02 | 2023-03-16 | The George Washington University | Systems and methods for triple-parametric optical mapping |
| US11467151B1 (en) | 2021-12-23 | 2022-10-11 | United Arab Emirates University | Phosphorescence oxygen analyzer and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4115699A (en) | 1977-06-16 | 1978-09-19 | Kabushiki Kaisha Nihon Kotai Kenkyujo | Apparatus for sensitive detection and quantitative analysis of biological and biochemical substances |
| US4476870A (en) | 1982-03-30 | 1984-10-16 | The United States Of America As Represented By The Department Of Health And Human Services | Fiber optic PO.sbsb.2 probe |
| DE3245939C2 (de) | 1982-12-11 | 1985-12-19 | Fa. Carl Zeiss, 7920 Heidenheim | Vorrichtung zur Erzeugung eines Bildes des Augenhintergrundes |
| US4810655A (en) | 1985-07-03 | 1989-03-07 | Abbott Laboratories | Method for measuring oxygen concentration |
| US5120510A (en) | 1986-10-10 | 1992-06-09 | Minnesota Mining And Manufacturing Company | Sensor and method for sensing the concentration of a component in a medium |
| US4947850A (en) | 1988-03-11 | 1990-08-14 | Trustees Of The University Of Pennsylvania | Method and apparatus for imaging an internal body portion of a host animal |
| US5039219A (en) | 1989-05-26 | 1991-08-13 | Photon Technology | Luminescence system and method for determining the nature of substances by measuring fluorescence and phosphorescence properties |
| EP0471861B1 (en) | 1990-08-13 | 1995-11-08 | Hewlett-Packard GmbH | Optical probe |
| US5186173A (en) | 1990-08-14 | 1993-02-16 | Drexel University | Method for in vivo measurement of oxygen concentration levels |
| US5318023A (en) | 1991-04-03 | 1994-06-07 | Cedars-Sinai Medical Center | Apparatus and method of use for a photosensitizer enhanced fluorescence based biopsy needle |
| EP0515211A3 (en) | 1991-05-23 | 1993-04-07 | Becton Dickinson And Company | Apparatus and method for phase resolved fluorescence lifetimes of independent and varying amplitude pulses |
| US5281825A (en) | 1991-09-05 | 1994-01-25 | The University Of Maryland School Of Medicine | Phase fluorometry using a modulated electroluminescent lamp as a light source |
| US5341805A (en) | 1993-04-06 | 1994-08-30 | Cedars-Sinai Medical Center | Glucose fluorescence monitor and method |
| US5383452A (en) | 1993-07-01 | 1995-01-24 | Buchert; Janusz | Method, apparatus and procedure for non-invasive monitoring blood glucose by measuring the polarization ratio of blood luminescence |
| US5515864A (en) | 1994-04-21 | 1996-05-14 | Zuckerman; Ralph | Method and apparatus for the in vivo measurement of oxygen concentration levels by the indirect determination of fluoescence lifetime |
| US5701902A (en) | 1994-09-14 | 1997-12-30 | Cedars-Sinai Medical Center | Spectroscopic burn injury evaluation apparatus and method |
| US6007994A (en) * | 1995-12-22 | 1999-12-28 | Yale University | Multiparametric fluorescence in situ hybridization |
| AU730100B2 (en) * | 1997-02-27 | 2001-02-22 | Cellomics, Inc. | A system for cell-based screening |
| CA2332833A1 (en) | 1998-05-19 | 1999-11-25 | Spectrx, Inc. | Apparatus and method for determining tissue characteristics |
| IL125614A (en) * | 1998-07-31 | 2003-01-12 | Amiram Grinvald | System and method for non-invasive imaging of retinal function |
| EP1475037B1 (en) | 2002-02-14 | 2012-09-12 | Toshinori Kato | Apparatus for evaluating biological function |
| JP2007516009A (ja) | 2003-10-03 | 2007-06-21 | アカデミッシュ メディシュ セントラム | 基質の反射の画像処理のためのシステム及び方法。 |
-
2007
- 2007-01-19 US US11/624,820 patent/US8129105B2/en not_active Expired - Fee Related
- 2007-03-12 AU AU2007238412A patent/AU2007238412B2/en not_active Ceased
- 2007-03-12 JP JP2009505524A patent/JP2009533160A/ja active Pending
- 2007-03-12 EP EP07758327A patent/EP2004040A4/en not_active Ceased
- 2007-03-12 CA CA2648931A patent/CA2648931C/en active Active
- 2007-03-12 WO PCT/US2007/063768 patent/WO2007121009A2/en not_active Ceased
- 2007-10-10 US US11/870,355 patent/US8309346B2/en not_active Expired - Fee Related
-
2012
- 2012-11-09 US US13/673,377 patent/US9215982B2/en active Active
- 2012-11-21 JP JP2012255630A patent/JP2013078592A/ja active Pending
-
2015
- 2015-07-30 JP JP2015151263A patent/JP6240833B2/ja not_active Expired - Fee Related
- 2015-12-18 US US14/974,550 patent/US9462951B2/en not_active Expired - Fee Related
-
2016
- 2016-10-07 US US15/288,840 patent/US10004401B2/en active Active
-
2018
- 2018-06-22 US US16/015,659 patent/US10194804B2/en active Active
-
2019
- 2019-01-22 US US16/253,633 patent/US10542891B2/en active Active
-
2020
- 2020-01-24 US US16/751,678 patent/US11064890B2/en not_active Expired - Fee Related
-
2021
- 2021-07-19 US US17/379,227 patent/US11717166B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11064890B2 (en) | 2021-07-20 |
| US9462951B2 (en) | 2016-10-11 |
| US8129105B2 (en) | 2012-03-06 |
| US20080254531A1 (en) | 2008-10-16 |
| US20190254526A1 (en) | 2019-08-22 |
| JP6240833B2 (ja) | 2017-12-06 |
| US20130072769A1 (en) | 2013-03-21 |
| US10194804B2 (en) | 2019-02-05 |
| US20220039655A1 (en) | 2022-02-10 |
| WO2007121009A2 (en) | 2007-10-25 |
| JP2009533160A (ja) | 2009-09-17 |
| JP2016000215A (ja) | 2016-01-07 |
| EP2004040A2 (en) | 2008-12-24 |
| US20170150887A1 (en) | 2017-06-01 |
| US20070243521A1 (en) | 2007-10-18 |
| CA2648931A1 (en) | 2007-10-25 |
| US20200329971A1 (en) | 2020-10-22 |
| US8309346B2 (en) | 2012-11-13 |
| US10004401B2 (en) | 2018-06-26 |
| US10542891B2 (en) | 2020-01-28 |
| AU2007238412B2 (en) | 2013-07-04 |
| WO2007121009A3 (en) | 2008-03-06 |
| US11717166B2 (en) | 2023-08-08 |
| US20160174845A1 (en) | 2016-06-23 |
| EP2004040A4 (en) | 2010-05-26 |
| JP2013078592A (ja) | 2013-05-02 |
| US20180360318A1 (en) | 2018-12-20 |
| WO2007121009B1 (en) | 2008-04-17 |
| US9215982B2 (en) | 2015-12-22 |
| AU2007238412A1 (en) | 2007-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11717166B2 (en) | Method and apparatus for the non-invasive measurement of tissue function and metabolism by determination of steady-state fluorescence anisotropy | |
| US8078267B2 (en) | Imaging of macular pigment distributions | |
| JP3579424B2 (ja) | 定常状態でのルミネセンスの存続時間による分析物の検出 | |
| KR101599077B1 (ko) | 류마티스 관절염 등의 염증성 질환의 진단 또는 진단 준비 및/또는 치료 모니터링 장치 및 절차 | |
| KR20100106965A (ko) | 눈과 관련된 질환을 검출하기 위한 방법 및 장치 | |
| Rovati et al. | Autofluorescence methods in ophthalmology | |
| JP4721144B2 (ja) | 測定方法および測定装置 | |
| JP2005195379A (ja) | 腫瘍画像検出方法とその装置 | |
| Model et al. | System for determining the concentration and visualization of the spatial distribution of photosensitizers based on tetrapyrrole compounds in the tissues of the human ocular fundus | |
| Pfefer et al. | Long‐term Effects of Photodynamic Therapy on Fluorescence Spectroscopy in the Human Esophagus¶ | |
| Schweitzer | Autofluorescence diagnostics of ophthalmic diseases | |
| Troyanova et al. | Fluorescence and reflectance properties of hemoglobin-pigmented skin disorders | |
| Kałużyński et al. | Luminescence spectroscopy measurements for skin cancer research | |
| Schweitzer | 20 Ophthalmic | |
| Paspa et al. | Fluorescence fiber optic probe with distance correction for endoscopic use | |
| Papour | Fast biomedical imaging using fluorescence lifetime and unique Raman signatures |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |